-
Mashup Score: 3The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation | Clinical Research Trial Listing - 2 month(s) ago
REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.
Source: www.centerwatch.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 3Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials - 6 month(s) ago
In this thought leadership piece for CenterWatch Weekly, Jonathan Seltzer, executive director of the Cardiac Safety Research Consortium (CSRC), a partnership of industry, government and academic leaders, discusses the use of remote patient monitoring in cardiac clinical trials.
Source: www.centerwatch.comCategories: General Medicine News, CardiologistsTweet-
Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials | CenterWatch @AliveCor https://t.co/LJ5LVcb4YZ
-
-
Mashup Score: 0Study Supports Implementation of eConsent, Finding Benefits over Traditional Methods - 1 year(s) ago
Electronic informed consent (eConsent) appears to be just as easy, if not easier, for patients to use and understand as traditional paper-based consenting and improves consent document completion, a recently published study has found. Experts say these findings should give sites greater confidence in taking on eConsent solutions.
Source: www.centerwatch.comCategories: Future of Medicine, Latest HeadlinesTweet-
✅ 235 eConsents completed with zero deficiencies VS 🚫 235 Paper Consents completed with 15 deficiencies. 🤗 940 complete responses: 82.7% felt eConsent was easy or very easy to use. Learn more about the benefits of eConsent in clinical trials, here: https://t.co/5d9rYVlSlg
-
-
Mashup Score: 0
It’s been widely agreed that technology is the greatest hurdle sites face in implementing decentralized trial (DCT) components, but a recent think tank discussion has unveiled a new revelation: sites are now naming unclear regulatory requirements as the top barrier they face as DCTs continue to take form.
Source: www.centerwatch.comCategories: Future of Medicine, Latest HeadlinesTweet-
How do we get all sites onboard with DCTs? Medable, @SyneosHealth & @AdvClinical facilitated a discussion with industry experts, & found there is a critical need for unified guidance regarding the oversight of remote trials. Read the group’s observations: https://t.co/AA2BzDwh9G
-
-
Mashup Score: 0
A Senate committee will vote on Robert Califf’s nomination to become FDA commissioner on Wednesday, Jan. 12, an essential step before the full chamber can hold a confirmation vote on Biden’s pick to lead the nation’s drug regulator.
Source: www.centerwatch.comCategories: Cardiologists, Latest HeadlinesTweet-
Happening this week! Senate Committee Vote on @califf001 for FDA Commissioner - Wednesday 🤞 @hfcollaboratory https://t.co/ARieBT7hXM
-
-
Mashup Score: 0
Oncology trials are bogged down by a number of serious challenges that significantly impact sites and research timelines. Decentralized trial (DCT) approaches could simplify many of these complexities, but hesitancy about adoption still remains.
Source: www.centerwatch.comCategories: Future of Medicine, Latest HeadlinesTweet-
Approximately 30% of patients in cancer trials will quit, leading to huge cost and time implications for sites & sponsors. Medable's Archana Sah discussed with @CenterWatch how DCTs can accelerate Oncology trial timelines while boosting retention. Read: https://t.co/D8njfkEIkQ
-
-
Mashup Score: 0What a Califf-Led FDA May Look Like the Second Time Around - 2 year(s) ago
If Robert Califf’s nomination to helm the FDA a second time succeeds in Congress, he is likely to push for clinical research reforms, with a focus on diversity, the increased use of real-world evidence (RWE) and addressing the rising costs and complexity of trials.
Source: www.centerwatch.comCategories: Future of Medicine, Latest HeadlinesTweet-
"I believe Califf will look to harness & expand the unprecedented drug & vaccine acceleration that took place during the pandemic", offered Medable CGO Sanskriti Thakur when discussing with @CenterWatch what the future of the FDA could look like. Read: https://t.co/oeVZk7bwvz
-
-
Mashup Score: 0
Trial startups are taking longer and longer, with approaches used so far failing to consistently speed up the pace despite some success in addressing growing trial complexity.
Source: www.centerwatch.comCategories: Future of Medicine, Latest HeadlinesTweet-
Mary Costello & Dr. Pamela Tenaerts recently spoke with @CenterWatch & addressed the growing complexity of clinical trials & longer start-up times. Read the full article here: https://t.co/Bn2lr8857b #decentralizedtrials #clinicaltrials #healthcare #lifesciences #medicine https://t.co/PgYJCNBCsG
-
-
Mashup Score: 1Use of Master Protocols Expected to Grow in Wake of FDA Guidance - 3 year(s) ago
The use of master protocols in the U.S. will likely increase and expand into more treatment areas now that the FDA has signaled support for the practice in a new final guidance for COVID-19 trials last week.
Source: www.centerwatch.comCategories: Future of Medicine, Latest HeadlinesTweet-
Numerous Medable-powered digital studies have witnessed up to 15% improvments in protocol adherence. Dr. Pamela Tenaerts elabortes on the shift to Master Protocol deployment following the FDA's new guidelines: https://t.co/nA4m14HVtP #decentralizedtrials #clinicaltrials https://t.co/YmhyCCieGJ
-
-
Mashup Score: 7
Clinical trial for Pacemaker (ICD) , Clinical, Electrocardiographic, and Cardiac Magnetic Resonance Imaging Risk Factors Associated with Ventricular Tachyarrhythmias in Nonischemic Cardiomyopathy (MARVEN Study)
Source: www.centerwatch.comCategories: Cardiologists, Latest HeadlinesTweet-
My bet is LGE on MRI predicts ICD benefit in this population. We are enrolling in NIH sponsored MARVEN study to help find out might do well with CRT-P. https://t.co/YTCzDcb5Xq https://t.co/7tPvW2iXJs
-
@netta_doc @PassmanRod @nmarrouche @westernAFib @AndreaRussoEP @NorthwesternMed What was the take? I love the question React-AF is taking on and am presenting on pt wearables in #AFib at @UtahAPA RedRockCME 03/2024. Trial design: https://t.co/3emTm0ToUb https://t.co/TYyWgosFdc